EP3336082

TRANSLATE BIO, INC.
Application Number
EP18153312A
Filing Date
Jun 8, 2012
Status
Revoked
Aug 26, 2022
Grant Date
Apr 15, 2020
External Links
Slate, Register

Biblio Summary

The patent EP3336082B1 was granted on Apr 15, 2020 by Translate Bio, Inc. The patent is currently Revoked.

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DILG, HAEUSLER, SCHINDELMANN PATENTANWALTSGESELLSCHAFT MBHJan 15, 2021ADMISSIBLE
GLAXOSMITHKLINE BIOLOGICALS SAJan 15, 2021ADMISSIBLE

The table below shows the patents of Translate Bio, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2858679Pulmonary Delivery Of Mrna To Non-Lung Target CellsJun 5, 20241
EP3501605Mrna Therapy For Argininosuccinate Synthetase DeficiencyJun 28, 20231
EP2970456Methods And Compositions For Delivering Mrna Coded AntibodiesMay 19, 20214

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.